EyePoint Pharmaceuticals Inc. (EYPT) announced positive interim safety and efficacy data from phase 1 DAVIO clinical trial evaluating EYP-1901 for the Treatment of wet age-related macular degeneration.
The interim six-month results showed positive safety data, no dose limiting toxicities, no ocular serious adverse events (SAEs), and no drug-related systemic serious adverse events.
The data showed 76% and 53% of patients did not require rescue following a single dose of EYP-1901 up to four and six months, stable and sustained BCVA (-2.5 letters) and CST (-2.7 µm), a 79% reduction in treatment burden at six months, and a median time to rescue of six months across all patients.
The Phase 1 DAVIO clinical trial is an open-label, dose escalation clinical trial of EYP-1901 that enrolled 17 patients with previously treated wet age-related macular degeneration.
EYP-1901 is a sustained delivery anti-VEGF (voralanib) investigational treatment that utilizes a bioerodible formulation of EyePoint's Durasert drug delivery technology that has been utilized in four FDA-approved products, including EyePoint's YUTIQ for chronic non-infectious uveitis affecting the posterior segment of the eye.
EyePoint plans to initiate a Phase 2 wet AMD clinical trial in 2022 and the company has scheduled a Type C meeting with the FDA on December 1, 2021, to discuss specific plans and obtain guidance on potential EYP-1901 registration trials.
The company also expects to initiate additional EYP-1901 clinical trials in diabetic retinopathy (DR) and retinal vein occlusion (RVO).
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.